Overview

Food-Effect Bioavailability Study of FDC(Gemigliptin/Metformin HCl Sustained Release) 50/1000mg(25/500mg x 2tablets)

Status:
Completed
Trial end date:
2013-04-01
Target enrollment:
Participant gender:
Summary
This study is designed to investigate the food-effects on FDC(gemigliptin/metformin HCl sustained release) 50/1000mg(25/500mg x 2tablets)
Phase:
Phase 1
Details
Lead Sponsor:
LG Life Sciences
Treatments:
Metformin